What is IVF's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IVF?

P/E (TTM) is n/a and 52-week range is $0.58 to $84.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IVF figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IVF?

The company profile lists revenue (TTM) near $7M, net income (TTM) near $-469M, EPS (TTM) near $-28.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is INVO Fertility Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Sarasota, Florida, US, 2.3M shares outstanding, ISIN US44984F8804 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

INVO Fertility Inc

$IVF

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.55

-6.51%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

INVO Fertility, Inc. operates as a revenue-generating fertility business. The company is headquartered in Sarasota, Florida and currently employs 28 full-time employees. The company went IPO on 2008-11-11. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. The company focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. The company has two operational INVO Centers in the United States and one IVF clinic. The company is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.

Employees

Website

invofertility.com/

IPO

2008-11-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)